Overview
Human menopausal gonadotropin is a biologically derived preparation, traditionally purified from the urine of postmenopausal women, that provides both follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity in roughly balanced amounts. It is standardized by international units of biological activity rather than by mass.
HMG is a long-established, approved fertility medicine (menotropin) and has been studied extensively for ovulation induction and assisted-reproduction protocols, often in combination with HCG.
Mechanism of action
Research and clinical pharmacology indicate HMG works through its two gonadotropin components. The FSH activity stimulates follicular growth and gametogenesis, while the LH activity supports steroidogenesis and follicular maturation.
By supplying both signals, HMG mimics the combined gonadotropin output of the pituitary, which is the basis for its use in stimulating the reproductive axis at the gonadal level.
Research findings
Has been studied and clinically used for ovulation induction via combined FSH and LH activity.,Research suggests its FSH component drives follicular development.,Studied in assisted-reproduction protocols, frequently alongside HCG.,Used to support gametogenesis in both female and male fertility contexts.,Standardized by biological activity (international units) rather than mass.
Research context
HMG is dosed and studied in international units of biological activity, and its components show biphasic clearance with the FSH activity having a half-life on the order of several hours. Its pharmacokinetics are characterized through extensive clinical fertility use, with parameters varying by protocol and population. This entry summarizes findings at a high level only. This is a research reference only. Not approved for human use outside regulated settings; consult the primary literature.
Handling & storage
Lyophilized preparation is typically stored at refrigerated or -20 degrees Celsius conditions for long-term laboratory storage and protected from light and moisture. After reconstitution in a laboratory context it is generally refrigerated and used within a limited window per established protocols. Avoid repeated freeze-thaw cycles.
Reported safety signals
Clinical literature reports effects related to its gonadotropic activity, including injection-site reactions and, in fertility contexts, ovarian hyperstimulation considerations. Effects relate to its reproductive-axis stimulation. Safety characterization should rely on the primary literature.
Studied alongside
In fertility protocols HMG is classically studied together with HCG, which provides additional LH-like activity to complete follicular maturation. It is also discussed alongside axis modulators such as gonadorelin and kisspeptin-10 in reproductive research.
At a glance
Research strengths
- Provides both FSH-like and LH-like activity in one preparation.
- Established, approved fertility medicine with extensive data.
- Central component of assisted-reproduction protocols.
- Standardized by biological activity for consistent potency.
Limitations & cautions
- Hormonal activity carries risks such as ovarian hyperstimulation.
- Biologically derived preparation, not a single defined molecule.
- Requires careful clinical oversight in approved use.
- Molar mass is not meaningfully defined for a mixed preparation.
